- Scientists have developed a new way to improve CAR T-cell therapy for blood cancers.
- CAR T-cell therapy involves genetically modifying a patient’s T cells to recognize and attack cancer cells.
- The researchers added two co-stimulatory molecules, CD28 and CD40, to the CAR T cells.
- This modification enhanced the CAR T cells’ ability to kill cancer cells and improved their persistence.
- This approach could lead to better outcomes for patients with B-cell malignancies.
Funding
- Faculty of Medicine, Prince of Songkla University
- Southern Science Park, Prince of Songkla University
- National Research Council of Thailand (NRCT)
- Royal King Ananda Mahidol Foundation
Original Paper
Title of original paper: Co-stimulation of CD28/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness
Journal: Molecular Therapy: Oncology
DOI: https://doi.org/10.1016/j.omton.2024.200837